000			01733 a2200469 4500
005			20250517143907.0
264		0	_c20180315
008			201803s 0 0 ger d
022			_a2193-6226
024	7		_a10.1007/s00063-017-0271-3 _2doi
040			_aNLM _beng _cNLM
100	1		_aRademacher, J
245	0	0	_a[New antibiotics - standstill or progress]. _h[electronic resource]
260			_bMedizinische Klinik, Intensivmedizin und Notfallmedizin _cApr 2017
300			_a206-213 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Review
650	0	4	_aAnti-Bacterial Agents _xadverse effects
650	0	4	_aAzabicyclo Compounds _xtherapeutic use
650	0	4	_aBacterial Infections _xdrug therapy
650	0	4	_aCeftazidime _xtherapeutic use
650	0	4	_aCephalosporins _xadverse effects
650	0	4	_aClinical Trials as Topic
650	0	4	_aDrug Approval
650	0	4	_aDrug Combinations
650	0	4	_aDrug Resistance, Multiple, Bacterial
650	0	4	_aEphedrine
650	0	4	_aHumans
650	0	4	_aMacrolides _xadverse effects
650	0	4	_aMethicillin-Resistant Staphylococcus aureus _xdrug effects
650	0	4	_aOrganophosphates _xadverse effects
650	0	4	_aOxazoles _xadverse effects
650	0	4	_aPenicillanic Acid _xadverse effects
650	0	4	_aPhenobarbital
650	0	4	_aStaphylococcal Infections _xdrug therapy
650	0	4	_aTazobactam
650	0	4	_aTheophylline
650	0	4	_aTriazoles _xadverse effects
650	0	4	_aCeftaroline
700	1		_aWelte, T
773	0		_tMedizinische Klinik, Intensivmedizin und Notfallmedizin _gvol. 112 _gno. 3 _gp. 206-213
856	4	0	_uhttps://doi.org/10.1007/s00063-017-0271-3 _zAvailable from publisher's website
999			_c26988997 _d26988997